InsiderTrades.com logo
Brian Piekos net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Brian Piekos Biography and Net Worth

CFO of KalVista Pharmaceuticals

Brian Piekos has more than 25 years of financial and strategic planning experience in the biopharmaceutical industry. He joins KalVista from Elicio Therapeutics where he served as CFO and was responsible for launching Elicio as a public company. Previously, he served as CFO for Gemini Therapeutics and as Executive Vice President, CFO and Treasurer at AMAG Pharmaceuticals. Mr. Piekos held leadership roles in corporate finance, tax and treasury at Cubist Pharmaceuticals and began his career as a healthcare investment banker at Needham & Company and Leerink Partners.

Mr. Piekos earned his B.A. in biochemistry from Ithaca College, an M.S. in molecular biology from the University of Massachusetts Medical School, and his MBA from the Simon Business School at the University of Rochester.

What is Brian Piekos' net worth?

The estimated net worth of Brian Piekos is at least $486.24 thousand as of April 17th, 2026. Piekos owns 18,150 shares of KalVista Pharmaceuticals stock worth more than $486,239 as of May 22nd. This net worth approximation does not reflect any other assets that Piekos may own. Learn More about Brian Piekos' net worth.

How do I contact Brian Piekos?

The corporate mailing address for Piekos and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at [email protected]. Learn More on Brian Piekos' contact information.

Has Brian Piekos been buying or selling shares of KalVista Pharmaceuticals?

In the last ninety days, Brian Piekos has sold $37,649.64 in shares of KalVista Pharmaceuticals stock. Most recently, Brian Piekos sold 1,862 shares of the business's stock in a transaction on Friday, April 17th. The shares were sold at an average price of $20.22, for a transaction totalling $37,649.64. Following the completion of the sale, the chief financial officer now directly owns 18,150 shares of the company's stock, valued at $366,993. Learn More on Brian Piekos' trading history.

Who are KalVista Pharmaceuticals' active insiders?

KalVista Pharmaceuticals' insider roster includes Paul Audhya (Insider), Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Benjamin Palleiko (Chief Executive Officer and Director), Brian Piekos (CFO), Michael Smith (VP), Nicole Sweeny (Insider), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.

Are insiders buying or selling shares of KalVista Pharmaceuticals?

During the last year, insiders at the specialty pharmaceutical company sold shares 29 times. They sold a total of 367,770 shares worth more than $6,082,852.55. The most recent insider tranaction occured on May, 12th when CEO Benjamin L Palleiko sold 3,322 shares worth more than $88,730.62. Insiders at KalVista Pharmaceuticals own 4.3% of the company. Learn More about insider trades at KalVista Pharmaceuticals.

Information on this page was last updated on 5/12/2026.

Brian Piekos Insider Trading History at KalVista Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2026Sell1,862$20.22$37,649.6418,150View SEC Filing Icon  
2/23/2026Sell1,767$15.57$27,512.1913,762View SEC Filing Icon  
11/24/2025Sell4,471$13.45$60,134.9510,529View SEC Filing Icon  
See Full Table

Brian Piekos Buying and Selling Activity at KalVista Pharmaceuticals

This chart shows Brian Piekos's buying and selling at KalVista Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $26.79
Low: $26.77
High: $26.80

50 Day Range

MA: $21.35
Low: $15.49
High: $26.81

2 Week Range

Now: $26.79
Low: $9.83
High: $26.85

Volume

1,565,726 shs

Average Volume

7,435,951 shs

Market Capitalization

$1.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A